Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Cited by (1,001)

Items 701–800 of 1,001

1. Sclerostin within the chronic kidney disease spectrum
   Antoine Bouquegneau, Peter Evenepoel, François Paquot, Olivier Malaise, Etienne Cavalier, Pierre Delanaye · 2019 · Clinica Chimica Acta
2. Interrelationships Between Sclerostin, Secondary Hyperparathyroidism, and Bone Metabolism in Patients on Hemodialysis
   Yosuke Nakagawa, Hirotaka Komaba, Naoto Hamano, Hisae Tanaka, Takehiko Wada, Hiroaki Ishida, Michio Nakamura, Hiroo Takahashi, Yuichiro Takahashi, Toru Hyodo et al. · 2021 · The Journal of Clinical Endocrinology & Metabolism
3. Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice
   Masanori Koide, Teruhito Yamashita, Keigo Nakamura, Hisataka Yasuda, Nobuyuki Udagawa, Yasuhiro Kobayashi · 2022 · Bone
4. PHARMACOLOGICAL MANAGEMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: THE CURRENT STATE OF THE ART
   Davide Gatti, Angelo Fassio · 2019 · Journal of Population Therapeutics and Clinical Pharmacology
5. Foxf2 represses bone formation via Wnt2b/β-catenin signaling
   Tomoyuki N. Tanaka, Akira Takahashi, Yutaka Kobayashi, Masanori Saito, Sun Xiaolong, Chen Jingquan, Yoshiaki Ito, Tsuyoshi Kato, Hiroki Ochi, Shingo Sato et al. · 2022 · Experimental & Molecular Medicine
6. Design, Synthesis and Biological Evaluation of New Quinazolinone-Benzopyran-Indole Hybrid Compounds Promoting Osteogenesis Through BMP2 Upregulation
   Anirban Sardar, Alisha Ansari, Sampa Gupta, Shradha Sinha, Shubham Pandey, Divya Rai, Mukesh Kumar, Rabi Sankar Bhatta, Ritu Trivedi, Koneni V. Sashidhara · 2022 · European Journal of Medicinal Chemistry
7. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial
   Akimitsu Miyauchi, Etsuro Hamaya, Wenjing Yang, Kiyoshi Nishi, Cesar R. Libanati, Cae Tolman, Junichiro Shimauchi · 2020 · Journal of Bone and Mineral Metabolism
8. Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
   Alexander J. Rodríguez, Bo Abrahamsen · 2021 · JBMR Plus
9. What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?
   Ian R. Reid · 2022 · Expert Opinion on Drug Safety
10. Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment
    Crystal Cobb, Malinda Wu, Vin Tangpricha · 2025 · Therapeutic Advances in Endocrinology and Metabolism
11. Advancing care: optimizing osteoporosis treatment in the older and oldest old population
    Claudia Panait, Patrizia D’Amelio · 2025 · Aging Clinical and Experimental Research
12. Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study
    Masaki Hatano, Yusuke Sasabuchi, Akira Okada, Yuya Kimura, Hisatoshi Ishikura, Takeyuki Tanaka, Taku Saito, Sakae Tanaka, Hideo Yasunaga · 2025 · Annals of the Rheumatic Diseases
13. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
    Martina Kleber, Ioannis Ntanasis‐Stathopoulos, Meletios Athanasios Dimopoulos, Evangelos Terpos · 2019 · Expert Review of Hematology
14. Bone Health in Idiopathic Inflammatory Myopathies: Diagnosis and Management
    Anett Vincze, János Gaál, Zoltán Griger · 2021 · Current Rheumatology Reports
15. Discovery of Spiro[pyrrolidine-3,3′-oxindole] LXRβ Agonists for the Treatment of Osteoporosis
    Hao Chen, Pei Hua, Dane Huang, Yuting Zhang, Huihao Zhou, Jun Xu, Qiong Gu · 2022 · Journal of Medicinal Chemistry
16. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk
    Michael R. McClung, Donald Betah, Cynthia Deignan, Yifei Shi, Jen Timoshanko, Felicia Cosman · 2023 · Endocrine Practice
17. Wnt signaling pathway and sclerostin in the development of atherosclerosis and vascular calcification
    Piotr Kocełak, Monika Puzianowska‐Kuźnicka, Magdalena Olszanecka‐Glinianowicz, Jerzy Tadeusz Chudek · 2023 · Advances in Clinical and Experimental Medicine
18. Anti-sclerostin antibodies: a new frontier in fragility fractures treatment
    Giovanni Iolascon, Sara Liguori, Marco Paoletta, Giuseppe Toro, Antimo Moretti · 2023 · Therapeutic Advances in Musculoskeletal Disease
19. Influence of age on the efficacy of pharmacologic treatments on fracture risk reduction and increases in BMD: RCT results from the FNIH-ASBMR-SABRE project
    Marian Schini, Tatiane Vilaça, Eric Vittinghoff, Li‐Yung Lui, Susan K. Ewing, Austin R. Thompson, Douglas C. Bauer, Mary Bouxsein, Dennis M. Black, Richard Eastell · 2024 · Journal of Bone and Mineral Research
20. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials
    Joseph M. Lane, Bente Lomholt Langdahl, Mike D. Stone, A. Kurth, Mary K. Oates, Jen Timoshanko, Zhenxun Wang, Cesar R. Libanati, Felicia Cosman · 2024 · Osteoporosis International
21. A comprehensive review and advanced biomolecule-based therapies for osteoporosis
    Maqsood Ali, Yong‐Sik Kim · 2024 · Journal of Advanced Research
22. SCUBE3 promotes osteogenic differentiation and mitophagy in human bone marrow mesenchymal stem cells through the BMP2 / TGF ‐β signaling pathway
    Hongyu Chen, Xiaoyong Wu, Yinan Lan, Xijie Zhou, Ye Zhang, Long Long, Yuliang Zhong, Zhengan Hao, Weijun Zhang, Deting Xue · 2024 · The FASEB Journal
23. Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab
    Tomonori Kobayakawa, Yasuhide Kanayama, Yuji Hirano, Toshitaka Yukishima, Yukio Nakamura · 2024 · JBMR Plus
24. Sequential and combination therapy with romosozumab
    Tomonori Kobayakawa · 2025 · Journal of Bone and Mineral Metabolism
25. Sclerostin antibody inhibits skeletal deterioration in mice exposed to partial weight-bearing
    Jordan Spatz, Rachel Ellman, Alison Cloutier, Leeann D. Louis, M. van Vliet, D. Dwyer, Marina Stolina, H.Z. Ke, Mary Bouxsein · 2017 · Life Sciences in Space Research
26. The quest for new drugs to prevent osteoporosis-related fractures
    T. J. de Villiers · 2017 · Climacteric
27. Clinical aspects and management of osteoporosis and fragility fractures in patients with diabetes
    Manju Chandran · 2017 · Osteoporosis and Sarcopenia
28. Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?
    Gudrun C. Thurner, Johannes Haybaeck, Paul L. Debbage · 2021 · International Journal of Molecular Sciences
29. Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review
    Frideriki Poutoglidou, Efthimios Samoladas, Νikolaos Raikos, Dimitrios Kouvelas · 2021 · Journal of Clinical Densitometry
30. Endocrinology of bone mineralization: An update
    Arnaud Jannin, V. Kerlan, Rachel Desailloud · 2021 · Annales d Endocrinologie
31. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice
    Tori Kroon, Neharika Bhadouria, Paul Niziolek, Daniel Edwards, Roy B. Choi, Erica L. Clinkenbeard, Alexander G. Robling, Nilsson Holguin · 2020 · Journal of Bone and Mineral Research
32. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats
    Mikkel Bo Brent, Annemarie Brüel, Jesper Skovhus Thomsen · 2022 · Bone
33. Towards novel measurements of remodeling activity in cortical bone: implications for osteoporosis and related pharmaceutical treatments
    Lindsay L. Loundagin, DML Cooper · 2022 · European Cells and Materials
34. Bone Metabolism Markers in Thalassemia Major-Induced Osteoporosis: Results from a Cross-Sectional Observational Study
    Athanasios N. Tsartsalis, George Ι. Lambrou, Dimitrios N. Tsartsalis, Ioannis Papassotiriou, Eugenia D. Vlachou, Evangelos Terpos, George Panagiotis Chrousos, Christina Kanaka‐Gantenbein, Antonis Kattamis · 2019 · Current Molecular Medicine
35. Reduced Bone Modeling and Unbalanced Bone Remodeling: Targets for Antiresorptive and Anabolic Therapy
    Sabashini K. Ramchand, Ego Seeman · 2020 · Handbook of experimental pharmacology
36. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status
    Toshitsugu Sugimoto, Toshio Matsumoto, Takayuki Hosoi, Masataka Shiraki, Makiko Kobayashi, Naoki Okubo, Hideo Takami, Toshitaka Nakamura · 2020 · Journal of Bone and Mineral Metabolism
37. The intricate mechanism of PLS3 in bone homeostasis and disease
    Zhong, Wenchao, Pathak, Janak L., Liang, Yueting, Zhytnik, Lidiia, Pals, Gerard, Eekhoff, Elisabeth M. W., Bravenboer, Nathalie, Micha, Dimitra · 2023 · Frontiers in Endocrinology
38. Crosstalk between kidney and bones: New perspective for modulating osteoporosis
    Yan Duan, Lijuan Zhao, Yuting Lu, Juan Li, Shunxiang Li · 2025 · Ageing Research Reviews
39. Treatment of cystic fibrosis related bone disease
    Jagdeesh Ullal, KATHERINE A. KUTNEY, Kristen M. Williams, David R. Weber · 2021 · Journal of Clinical & Translational Endocrinology
40. Parathyroid hormone 1 receptor signaling mediates breast cancer metastasis to bone in mice
    Srilatha Swami, Hui Zhu, Aria Nisco, Takaharu Kimura, Matthew Kim, Vaisakh Nair, Joy Y. Wu · 2023 · JCI Insight
41. Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy
    Marciana L. Laster, Renata C. Pereira, Kathleen J. Noche, Barbara Gales, Isidro B. Salusky, Lauren Veronica Albrecht · 2023 · Nutrients
42. Effect of Romosozumab Treatment in Postmenopausal Women With Osteoporosis and Knee Osteoarthritis: Results From a Substudy of a Phase 3 Clinical Trial
    Nancy E. Lane, Donald Betah, Cynthia Deignan, Mary K. Oates, Zhenxun Wang, Jen Timoshanko, Aliya Aziz Khan, Neil Binkley · 2023 · ACR Open Rheumatology
43. Position Statement: Postmenopausal Osteoporosis Treatment Strategies in Korea
    So Young Park, Se Hwa Kim, Young‐Kyun Lee, Jung‐Ho Shin, Yong‐Chan Ha, Ho Yeon Chung · 2023 · Journal of Bone Metabolism
44. The Sequential Therapy in Osteoporosis
    Ravi Sauhta, Dheeraj Makkar, Pooja Sauhta Siwach · 2023 · Indian Journal of Orthopaedics
45. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study
    Akimitsu Miyauchi, Etsuro Hamaya, Junichiro Shimauchi, Yoko Yoshinaga, Kiyoshi Nishi · 2023 · Journal of Bone and Mineral Metabolism
46. A practical approach for anabolic treatment of bone fragility with romosozumab
    Luisella Cianferotti, Cristiana Cipriani, Andrea Palermo, Ombretta Viapiana, Guido Zavatta, Gherardo Mazziotti · 2024 · Journal of Endocrinological Investigation
47. Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK
    Fredrik Borgström, Mattias Lorentzon, Helena Johansson, Nicholas C. Harvey, Eugene McCloskey, Damon Willems, Douglas Knutsson, John A. Kanis · 2024 · Osteoporosis International
48. Romosozumab versus denosumab in long‐term users of glucocorticoids: A pilot randomized controlled trial
    Chi Chiu Mok, Kar Li Chan, Sau Mei Tse, Sammy Pak Lam Chen, K. C. B. Tan, Wai Han Ma · 2024 · Journal of Internal Medicine
49. Cardiovascular outcomes of romosozumab treatment—real-world data analysis
    Anat Tsur, Avivit Cahn, Ludmila Levy, Rena M. Pollack · 2024 · JBMR Plus
50. Molecular enhancement of fracture healing - Is there a role for Bone Morphogenetic Protein-2, parathyroid hormone, statins, or sclerostin-antibodies?
    Leopold Henssler, Maximilian Kerschbaum, Moldakulov Z. Mukashevich, Markus Rupp, Volker Alt · 2021 · Injury
51. Osteoinductive activity of bisdemethoxycurcumin and its synergistic protective effect with human amniotic mesenchymal stem cells against ovariectomy-induced osteoporosis mouse model
    Jinxing Wei, Yi Luo, Yan Xu, Jian‐Hui Xiao · 2022 · Biomedicine & Pharmacotherapy
52. Biochemical markers of bone turnover in osteoporosis
    Paweł Szulc, Douglas C. Bauer, Richard Eastell · 2020 · Elsevier eBooks
53. BHLHE40 promotes osteoclastogenesis and abnormal bone resorption via c-Fos/NFATc1
    Yufeng Zhang, Min Yang, Sheng Zhang, Zhiqiang Yang, Yufan Zhu, Yi Wang, Zhe Chen, Xuan Lv, Zan Huang, Yuanlong Xie et al. · 2022 · Cell & Bioscience
54. Tratamiento secuencial en osteoporosis. Nuevas tendencias
    E. Casado, José Luís Neyro · 2021 · Revista de Osteoporosis y Metabolismo Mineral
55. Denosumab as a Pharmacological Countermeasure Against Osteopenia in Long Duration Spaceflight
    A Rengel, Vienna Tran, Li Shean Toh · 2023 · Aerospace Medicine and Human Performance
56. Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures
    Danbi Park, Seo Eun Kim, Hong Kyung Shin, Junghan Seo, Jeong Kyun Joo, Chongman Kim, Sang Hyub Lee, Jin Hoon Park · 2023 · Neurospine
57. Management der Osteoporose nach Fragilitätsfrakturen
    Markus Gosch, Ulla Cordula Stumpf, Christian Kammerlander, Wolfgang Böcker, Hans-Jürgen Heppner, S. Wicklein · 2018 · Zeitschrift für Gerontologie und Geriatrie
58. Proceedings of the 2019 Santa Fe Bone Symposium: New Concepts in the Care of Osteoporosis and Rare Bone Diseases
    Edward Michael Lewiecki, John Paul Bilezikian, Risa Kagan, Deborah Krakow, Michael R. McClung, Paul D. Miller, Eric T. Rush, Christopher Shuhart, Nelson B. Watts, Elaine Wei-Yin Yu · 2019 · Journal of Clinical Densitometry
59. Primary osteoporosis in men: an unmet medical need
    Fabian A. Mendoza, Michelle Le Roux, Intekhab Ahmed · 2019 · Fertility and Sterility
60. Economic implications of osteoporotic fractures in postmenopausal women
    Jeenal Patel · 2020 · The American Journal of Managed Care
61. Disorders of the Endocrine System and of Metabolism
    Mark Schifter, Mark P McLean, Suma Sukumar · 2021 · Wiley eBooks
62. Strontium-incorporated hydroxyapatite nanocomposites promoting bone formation and angiogenesis by modulating M2 macrophage polarization in the bone microenvironment
    Jing Li, Cuimiao Zhang, Jiayi Li, Ruijing Gao, Mengzhen Yang, Linkang Yu, Wei Zhang, Guoqiang Zhou, Wenzeng Shen, Jinchao Zhang et al. · 2025 · Regenerative Biomaterials
63. Bisphosphonates in the Management of Patients with Postmenopausal Osteoporosis; Back to the Future
    Socrates E. Papapoulos, Polyzois Makras · 2025 · Pharmaceuticals
64. Diet-Induced Metabolic Dysregulation in Female Mice Causes Osteopenia in Adult Offspring
    Yu Shi, Jessica L. Saben, Guangxu He, Kelle H. Moley, Fanxin Long · 2020 · Journal of the Endocrine Society
65. The impact of sex steroids on osteonecrosis of the jaw
    Ranhee Kim, Sung Woo Kim, Hoon Kim, Seung‐Yup Ku · 2022 · Osteoporosis and Sarcopenia
66. What’s New in Osteoporosis and Fragility Fractures
    Derek G. Hansen, Teerapat Tutaworn, Joseph M. Lane · 2022 · Journal of Bone and Joint Surgery
67. Recommendations for the Pharmacological Treatment of Osteoporosis – Update 2023 of the German Osteoporosis Guideline
    Ralf Schmidmaier, Peyman Hadji, Peter Kern, Michael Drey, Franz Josef Jakob, Friederike E Thomasius · 2023 · Osteologie/Osteology
68. The Role of Bone Mineral Density in a Successful Lumbar Interbody Fusion: A Narrative Review
    Kyriakos Bekas, Christos Zafeiris · 2024 · Cureus
69. Toll-like receptor-2 induced inflammation causes local bone formation and activates canonical Wnt signaling
    Petra Henning, Ali Kassem, Anna Westerlund, Pernilla Lundberg, Cecilia Engdahl, Vikte Lionikaite, Pernilla Wikström, Jianyao Wu, Lei Li, Catharina Lindholm et al. · 2024 · Frontiers in Immunology
70. Activation of connexin hemichannels enhances mechanosensitivity and anabolism in disused and aged bone
    Dezhi Zhao, Chao Tu, Lidan Zhang, Teja Guda, Sumin Gu, Jean Xin Jiang · 2024 · JCI Insight
71. Clinical Utility of Bone Turnover Markers in Chronic Kidney Disease
    Praopilad Srisuwarn, Richard Eastell, Syazrah Salam · 2024 · Journal of Bone Metabolism
72. Sclerostin as a new target of diabetes-induced osteoporosis
    Yànhuá Lǐ, Yaheng Luo, Debin Huang, Lele Peng · 2024 · Frontiers in Endocrinology
73. Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
    Shi-Hsun Chiu, Wen‐Tien Wu, Ting-Kuo Yao, Cheng-Huan Peng, Kuang‐Ting Yeh · 2024 · Biomedicines
74. Immunotherapy in the management of inflammatory bone loss in osteoporosis
    Leena Sapra, Rupesh Kumar Srivastava · 2024 · Advances in protein chemistry and structural biology
75. Application of anti-Sclerostin therapy in non-osteoporosis disease models
    Christina M. Jacobsen · 2016 · Bone
76. Sclerostin Antibody–Induced Changes in Bone Mass Are Site Specific in Developing Crania
    Amanda L. Scheiber, David K Barton, Basma M. Khoury, Joan C. Marini, Donald L. Swiderski, Michelle S. Caird, Kenneth M. Kozloff · 2019 · Journal of Bone and Mineral Research
77. Genetics of Skeletal Disorders
    Fadil M. Hannan, Paul J. Newey, Michael P. Whyte, Rajesh V. Thakker · 2020 · Handbook of experimental pharmacology
78. Current and Emerging Treatment of Osteoporosis
    Laura Tafaro, Nicola Napoli · 2020 · Practical issues in geriatrics
79. How we can mitigate the side effects associated with systemic glucocorticoid after allogeneic hematopoietic cell transplantation
    Shigeo Fuji, Michael Thomas Byrne, Arnon Nagler, Mohamad Mohty, Bipin N. Savani · 2021 · Bone Marrow Transplantation
80. The Impact of COVID-19 on the Optimal Management of Osteoporosis
    Sung Hye Kong, Bo Kwon Hwang, Byung‐Ho Yoon · 2021 · Journal of Bone Metabolism
81. Effects of sclerostin antibody on bone healing
    Atsushi Mihara, Kiminori Yukata, Toshihiro Seki, Ryuta Iwanaga, Norihiro Nishida, Kenzo Fujii, Yuji Nagao, Takashi Sakai · 2021 · World Journal of Orthopedics
82. Targeting the Wnt signaling pathway for breast cancer bone metastasis therapy
    Jingyao Cui, Haoran Chen, Kaiwen Zhang, Xin Li · 2021 · Journal of Molecular Medicine
83. Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis
    Jiping Shen, Zheng Ke, Shuangshuang Dong, Minzhi Lv, Ying Yuan, Le Song, Kefen Wu, Kan Xu, Yu Hu · 2022 · Medical Science Monitor
84. Conditional Loss of Nmp4 in Mesenchymal Stem Progenitor Cells Enhances PTH-Induced Bone Formation
    Emily G. Atkinson, Michele Adaway, Daniel J. Horan, Crystal Korff, Angela J. Klunk, Ashley L. Orr, Katherine Ratz, Teresita Bellido, Lilian Irene Plotkin, Alexander G. Robling et al. · 2020 · Journal of Bone and Mineral Research
85. The Dietary and Non-Dietary Management of Osteoporosis in Adult-Onset Celiac Disease: Current Status and Practical Guidance
    Abdulbaqi A. Al-Toma, Amin Herman, Willem Frederik Lems, Chris Jacob Johan Mulder · 2022 · Nutrients
86. All the might of the osteocyte: emerging roles in chronic kidney disease
    Lauren Veronica Albrecht, Renata C. Pereira, Isidro B. Salusky · 2023 · Kidney International
87. Tmem161a regulates bone formation and bone strength through the P38 MAPK pathway
    Takuya Nagai, Tomohisa Sekimoto, Syuji Kurogi, Tomomi Ohta, Shihoko Miyazaki, Yoichiro Yamaguchi, Takuya Tajima, Etsuo Chosa, Mai Imasaka, Kumiko Yoshinobu et al. · 2023 · Scientific Reports
88. Romosozumab Treatment Converts Trabecular Rods into Trabecular Plates in Male Cynomolgus Monkeys
    Jonathan B. Matheny, Ashley M. Torres, Michael S. Ominsky, Christopher J. Hernandez · 2017 · Calcified Tissue International
89. Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties
    Si-Tu Xue, Lei Zhang, Zhuo-Song Xie, Jie Jin, Huifang Guo, Hong Yi, Zong‐Ying Liu, Zhuorong Li · 2020 · European Journal of Medicinal Chemistry
90. Genetics and Genomics of SOST: Functional Analysis of Variants and Genomic Regulation in Osteoblasts
    Núria Martínez‐Gil, Neus Roca‐Ayats, Mónica Cozar, Natalia García‐Giralt, Diana Ovejero, Xavier Nogués, Daniel Grinberg, Susana Balcells · 2021 · International Journal of Molecular Sciences
91. Postmenopausal osteoporosis: risk evaluation and treatment options
    Gloria Bonaccorsi, Monica Rizzati, Lara Salani, Melchiore Giganti · 2021 · Minerva Obstetrics and Gynecology
92. Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation
    Luyao Wang, Xiaohui Tao, Hewen Jiang, Shijian Ding, Ning Zhang, Xin Yang, Shenghang Wang, Yihao Zhang, Nanxi Li, Haitian Li et al. · 2026 · Bone Research
93. From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy
    Nainita Roy, Hanyu Liu, Allison L Horenberg, Arvind P. Pathak, Junyu Chen, Saravana Kumar Ramasamy, Martine Esther Cohen-Solal, Aline Bözec, Warren L. Grayson, Anjali P. Kusumbe · 2026 · Bone Research
94. Peroxisome proliferator activated receptor-γ in osteoblasts controls bone formation and fat mass by regulating sclerostin expression
    Soohyun P. Kim, Avery H. Seward, Jean G. Garcia-Diaz, Nathalie S. Alekos, Nicole R. Gould, Susan M. Aja, Joseph P. Stains, Michael J. Wolfgang, Ryan C. Riddle · 2023 · iScience
95. Romosozumab-associated medication-related osteonecrosis of the jaw
    Benjamin L. Palla, John Anderson, Michael Miloro, Sarah Loren Moles, Nicholas F. Callahan · 2023 · Oral and Maxillofacial Surgery Cases
96. Update on Atypical Femoral Fractures
    Paul A. Anderson, Stephen L. Kates, Nelson B. Watts · 2024 · Journal of Bone and Joint Surgery
97. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition
    Albert Sungsoo Kim, Victoria E Taylor, Ariel Castro-Martinez, Suraj Dhakal, Amjad Zamerli, Sindhu T. Mohanty, Ya Xiao, Marija K. Simic, Alyssa Pantalone, Julian Chu et al. · 2025 · Journal of Bone and Mineral Research
98. An update on the pharmacotherapy of osteoporosis
    Anush Shashidhara, Syed Haider Tahir, Zain Abbas Syed, Jeffrey Lee, Hasan Tahir · 2025 · Expert Opinion on Pharmacotherapy
99. Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-naïve primary osteoporosis: A retrospective cohort study
    Yuki Etani, Takaaki Noguchi, Toshitaka Yukishima, Tomonori Kobayakawa, Masafumi Kashii, Gensuke Okamura, Atsushi Goshima, Makoto Hirao, Taihei Miura, Takuya Kurihara et al. · 2025 · Bone
100. Impact of FRAX-based osteoporosis intervention using real world data
     Inbal Goldshtein, Sophia Ish‐Shalom, Moshe Leshno · 2017 · Bone